Curis Set For Transformative Year With Erivedge Skin Cancer Approval
This article was originally published in The Pink Sheet Daily
Approved nearly six weeks before the March 8 PDUFA date, Erivedge (vismodegib) will be available to treat advanced basal cell cancers in a week or two for about $7,500 a month wholesale, partner Genentech said.
You may also be interested in...
FDA clears AbbVie’s Technivie, Novartis’ Odomzo, a new indication for Amgen’s Kyprolis and Bristol’s Daklinza July 24 before its much anticipated approval of Regeneron/Sanofi’s Praluent.
With new drugs at hand to protect its Herceptin breast cancer franchise, Roche announced positive data for its rituximab replacement candidate and other steps in its plan to protect top-seller Rituxan/MabThera.
FDA approval of Curis/Genentech’s hedgehog inhibitor Erivedge validates the class, but basal cell carcinoma is only the ante; cancers exploit hedgehog signaling in a variety of ways yet to be elucidated.